About this episode

This episode explores the experimental tripeptide DT-109 and its potential in treating metabolic and cardiovascular diseases.

This source explores DT-109 , an experimental tripeptide that represents a novel approach to treating metabolic and cardiovascular diseases . By analyzing its structure and mechanism, the text highlights how this small molecule distinguishes itself from popular weight-loss drugs by stimulating natural GLP-1 production and directly altering liver metabolism.

People in this episode

Host: Infinity Peptides

Topics covered

• tripeptide
• metabolic health
• cardiovascular diseases
• GLP-1 production
• liver metabolism

Keywords

• DT-109
• tripeptide
• metabolic health
• GLP-1
• liver metabolism
• cardiovascular diseases
• weight-loss drugs

Mentioned in this episode

Products: DT-109

More episodes of Today's discussion

• Pinealon: The Science and Hype of Brain Bioregulators · September 7, 2026 · 21 min
• Dulaglutide: The Foundation of Modern Metabolic Medicine · August 31, 2026 · 21 min
• FOXO4-DRI: The Science and Hype of Senolytic Peptides · August 24, 2026 · 26 min
• Cerebrolysin: Clinical Science and Biohacking Analysis · August 17, 2026 · 23 min
• ADAMAX Peptide: Science, Hype, and Cognitive Potential · August 10, 2026 · 19 min
• Survodutide: The Metabolic Power of Dual Receptor Agonism · August 3, 2026 · 20 min

Explore listener stats, chart rankings, contacts and more on the Today's discussion podcast page.